Navigation Links
Two New Strategic Reports Expand Coverage Of BioTrend's Biosimilars Advisory Service
Date:4/1/2013

EXTON, Pa., April 1, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released two strategic components to its 2013 Biosimilars Advisory Service, which provides vital business planning insights and analysis in the evolving biosimilars space. The reports entitled Corporate Strategies and Global Pipelines, Pathways and Key Stakeholder Perspectives of Biosimilars analyze surveyed opinions of specialist physicians and payers in the United States and Europe and secondary market research to uncover critical trends in strategic development for commercially lucrative market segments.

"The Biosimilars Advisory Service has always been a highly valuable tool for understanding trends in a complex and dynamic market," said Andrew Merron , Ph.D., Senior Director, Biosimilars Research at Decision Resources Group. "These new reports aim to enhance the overall service by evaluating current market opinion to help understand globally focused business strategies, regulatory guidance in multiple markets and pipeline information."

BioTrends Research Group's Biosimilars Advisory Service also includes quarterly webinars detailing major industry developments, analyst insight addressing key market changes, therapeutic area-specific primary research and interactive annualized 10-year forecasts.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.Bio-Trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 For more information, contact:BioTrends Research Group Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com

emarshall@dresourcesgroup.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuro Intervention Market: New Strategic Landscape & Market Forecast
2. MDHI Receives Strategic Investment to Continue Strong Growth - Moves into Positive Operating Cash Flow for March 2013 Quarter
3. Saladax Biomedical Receives $22.4 Million Strategic Equity Investment From Shanghai Fosun Pharmaceutical
4. DDS Lab Announces Strategic Alliance with United Concordia
5. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
6. Evofem Announces Strategic Alliance with WomanCare Global
7. WebMD and Qualcomm Life Launch Strategic mHealth Collaboration
8. Imalux Corporation Engages Advisor to Explore Strategic Options
9. BioDrain Medical Retains KCSA Strategic Communications as Corporate Communications Counsel
10. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
11. Covaris and HORIBA Instruments Form Strategic Relationship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
(Date:3/29/2017)... -- The Global Health Innovative Technology Fund (GHIT Fund), ... infectious diseases around the globe, today announced 11 ... deliver a range of new innovative therapies for ... This latest round of targeted support includes funding ... pediatric formulation of a drug considered the gold ...
(Date:3/29/2017)... March 29, 2017 Optometrists have staunchly ... the highest standard in quality and care for ... its objective Wavefront-driven refraction technologies and process to ... enables an unprecedented level of refraction and correction ... relegated to Topgun Navy fighter pilots, but now ...
Breaking Medicine Technology:
(Date:3/29/2017)... New York City, NY (PRWEB) , ... March ... ... governing body for men’s and women’s professional squash, announced it has enlisted New ... marketing partner. The agency will develop and procure sponsorship opportunities for the ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
(Date:3/29/2017)... ... 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, ... with or without a referral. Dr. Cotey knows that interceptive orthodontics in ... When patients receive early treatment, they may achieve straight teeth with less treatment in ...
(Date:3/29/2017)... MD (PRWEB) , ... March 29, 2017 , ... ... is proud to announce the finalization of the company’s executive management team with prominent ... and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who ...
Breaking Medicine News(10 mins):